J. Velzing et al., Induction of protective immunity against Dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines, VACCINE, 17(11-12), 1999, pp. 1312-1320
Dengue (DEN) viruses (serotypes 1 to 4) are mosquito-borne flaviviruses whi
ch cause about fifty million human infections annually and represent an exp
anding public health problem in the tropics. At present, there are no safe
and effective vaccines which induce protective immunity to all four serotyp
es of DEN. Natural infection or vaccination with native and recombinant pro
teins may induce an immune response to the surface envelope E-protein which
was shown to be protective to super-infection with homologous serotype of
the virus. Purified recombinant E-protein was made in the baculovirus-Spodo
ptera frugiperda expression system. This protein induced neutralizing antib
odies in mice. These results prompted us to immunize cynomolgus monkeys (Ma
caca fascicularis) with either a live attenuated DEN-2 vaccine or the recom
binant E-protein complexed to aluminum hydroxide. After immunization, the m
onkeys were challenged with the homologous DEN virus. Serum was collected a
t several time points and a virus-specific antibody response including a vi
rus neutralizing antibody response was measured. Antibody kinetics and leve
ls were similar to those recorded in humans with a natural DEN-virus infect
ion. Virus isolation and type specific RT-PCR were performed on the serum s
amples. The virus was isolated from sham vaccinated control monkeys but not
from monkeys vaccinated with the live attenuated vaccine. One of the two m
onkeys immunized with the recombinant E-protein was also protected. Taken t
ogether these data indicate the potential of both candidate vaccines and st
ress the need for evaluation of different antigen presentation systems for
the development of a subunit vaccine approach for DEN. (C) 1999 Elsevier Sc
ience Ltd. All rights reserved.